| |||||||||||||||||||||||||||||||||||
# of Animals | Phenotype | Strain | Sex | Value | Units | Conditions | Record ID | Condition 1a | Condition 1b | Condition 2 | |||||||||||||||||||||||||
3 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 0 | % | phosphate buffered saline (0.2 ml) then phosphate buffered saline (0.1 ml) | 111027 | phosphate buffered saline (0.2 ml) | phosphate buffered saline (0.1 ml) | ||||||||||||||||||||||||||
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 0 | % | DHD/K12/TRb cells (1 X 10E6) | 111028 | DHD/K12/TRb cells (1 X 10E6) | |||||||||||||||||||||||||||
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 40 | % | DHD/K12/TRb cells (2 X 10E6) | 111029 | DHD/K12/TRb cells (2 X 10E6) | |||||||||||||||||||||||||||
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 80 | % | DHD/K12/TRb cells (3 X 10E6) | 111030 | DHD/K12/TRb cells (3 X 10E6) | |||||||||||||||||||||||||||
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 0 | % | DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) | 111031 | DHD/K12/TRb cells (1 X 10E6) | DHD/K12/TRb cells (0.5 X 10E6) | ||||||||||||||||||||||||||
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 0 | % | DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) | 111032 | DHD/K12/TRb cells (1 X 10E6) | DHD/K12/TRb cells (1 X 10E6) | ||||||||||||||||||||||||||
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 40 | % | DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) | 111033 | DHD/K12/TRb cells (1 X 10E6) | DHD/K12/TRb cells (1.5 X 10E6) |